Metabolism of crystals within the joint

Reumatismo

Volumn 63, Issue 4, 2011, Pages 221-229

  Oliviero, F ^a   Scanu, A ^a   Punzi, Leonardo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Basic calcium phosphate; Crystals; Metabolism; Monosodium urate; Pyrophosphate

Indexed keywords

URATE;

CALCIFICATION; CALCIUM METABOLISM; CARTILAGE MATRIX; CRYSTAL STRUCTURE; CRYSTALLIZATION; DISSOLUTION; FLOW CYTOMETRY; GOUT; HUMAN; MINERALIZATION; PHYSICAL CHEMISTRY; PRECIPITATION; PURINE METABOLISM; PURINE SYNTHESIS; REVIEW; SYNOVIAL FLUID; URIC ACID BLOOD LEVEL;

ARTHRITIS, GOUTY; BIOLOGICAL MARKERS; CALCIUM PHOSPHATES; CALCIUM PYROPHOSPHATE; CHONDROCALCINOSIS; CHONDROCYTES; CRYSTALLIZATION; DISEASE PROGRESSION; GOUT; HUMANS; HYPERURICEMIA; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE; URIC ACID;

EID: 84856617360     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Fuerst M, Bertrand J, Lammers L, et al. Calcification of articular cartilage in human osteoarthritis. Arthritis Rheum 2009; 60: 2694-703.
2. Neogi T. Asymptomatic hyperuricemia: perhaps not so benign? J Rheumatol 2008; 35: 734-7.
3. Richette P, Bardin T. Gout. Lancet 2010; 375: 318-28.
4. Kippen I, Klinenberg JR, Weinberger A, Wilcox WR. Factors affecting urate solubility in vitro. Ann Rheum Dis 1974; 33: 313-7.
5. Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 1972; 15: 189-92.
6. Lindgarde F. Potentiometric determination of serum ionized calcium in a normal human population. Clin Chim Acta 1972; 40: 477-84.
7. Wilcox WR, Khalaf AA. Nucleation of monosodium urate crystals. Ann Rheum Dis 1975; 34: 332-7.
8. Maclachlan MJ, Rodnan GP. Effect of food, fast and alcohol on serum uric acid and acute attacks of gout. Am J Med 1967; 42: 38-57.
9. Seegmiller J, Laster L, Howell R. Biochemistry of uric acid and its relation to gout. N Engl J Med 1963; 268: 712-6.
10. Katz WA, Schubert M. The interaction of monosodium urate with connective tissue components J Clin Invest 1970; 49: 1783-9.
11. Kaneko K, Maru M. Determination of urate crystal formation using flow cytometry and microarea X-ray diffractometry. Anal Biochem 2000; 281: 9-14.
12. McGill NW, Dieppe PA. Evidence for a promoter of urate crystal formation in gouty synovial fluid. Ann Rheum Dis 1991; 50: 558-61.
13. McGill NW, Hayes A, Dieppe PA. Morphological evidence for biological control of urate crystal formation in vivo and in vitro. Scand J Rheumatol 1992; 21: 215-9.
14. Burt HM, Dutt YC. Growth of monosodium urate monohydrate crystals: effect of cartilage and synovial fluid components on in vitro growth rates. Ann Rheum Dis 1986; 45: 858-64.
15. Kam M, Perl-Treves D, Caspi D, Addadi L. Antibodies against crystals. FASEB J 1992; 6: 2608-13.
16. Perl-Treves D, Addadi L. A structural approach to pathological crystallizations. Gout: the possible role of albumin in sodium urate crystallization. Proc R Soc Lond B Biol Sci 1988; 235: 145-59.
17. Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007; 66: 1056-8.
18. Thiele RG, Schlesinger N. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int 2010; 30: 495-503.
19. Kozin F, McCarty DJ. Protein binding to monosodium urate monohydrate, calcium pyrophosphate dihydrate, and silicon dioxide crystals. I. Physical characteristics. J Lab Clin Med 1977; 89: 1314-25.
20. Terkeltaub R, Smeltzer D, Curtiss LK, Ginsberg MH. Low density lipoprotein inhibits the physical interaction of phlogistic crystals and inflammatory cells. Arthritis Rheum 1986; 29: 363-70.
21. Scanu A, Oliviero F, Gruaz L, et al. Highdensity lipoproteins downregulate CCL2 production in human fibroblast-like synoviocytes stimulated by urate crystals. Arthritis Res Ther 2010; 12: R23.
22. Burt HM, Jackson JK, Rowell J. Calcium pyrophosphate and monosodium urate crystal interactions with neutrophils: effect of crystal size and lipoprotein binding to crystals. J Rheumatol 1989; 16: 809-17.
23. Yagnik DR, Evans BJ, Florey O, et al. Macrophage release of transforming growth factor beta1 during resolution of monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2004; 50: 2273-80.
24. Akahoshi T, Namai R, Murakami Y, et al. Rapid induction of peroxisome proliferator-activated receptor gamma expression in human monocytes by monosodium urate monohydrate crystals. Arthritis Rheum 2003; 48: 231-9.
25. Landis RC, Yagnik DR, Florey O, et al. Safe disposal of inflammatory monosodium urate monohydrate crystals by differentiated macrophages. Arthritis Rheum 2002; 46: 3026-33.
26. Caswell A, Guilland-Cumming DF, Hearn PR, et al. Pathogenesis of chondrocalcinosis and pseudogout. Metabolism of inorganic pyrophosphate and production of calcium pyrophosphate dihydrate crystals. Ann Rheum Dis 1983; 42: 27-37.
27. Masuda I, Halligan BD, Barbieri JT, et al. Molecular cloning and expression of a porcine chondrocyte nucleotide pyrophosphohydrolase. Gene 1997; 197: 277-87.
28. Johnson K, Vaingankar S, Chen Y, et al. Differential mechanisms of inorganic pyrophosphate production by plasma cell membrane glycoprotein-1 and B10 in chondrocytes. Arthritis Rheum 1999; 42: 1986-97.
29. Johnson KA, Hessle L, Vaingankar S, et al. Osteoblast tissue-nonspecific alkaline phosphatase antagonizes and regulates PC-1. Am J Physiol Regul Integr Comp Physiol 2000; 279: R1365e77.
30. Hirose J, Ryan LM, Masuda I. Up-regulated expression of cartilage intermediate-layer protein and ANK in articular hyaline cartilage from patients with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum 2002; 46: 3218-29.
31. Crepaldi G, Punzi L. Aging and osteoarthritis. Aging Clin Exp Res 2003; 15: 355-8.
32. Blumenthal NC. Mechanisms of inhibition of calcification. Clin Orthop Relat Res 1989;247:279-89.
33. Terkeltaub R. Inorganic pyrophosphate (PPi) generation and disposition in pathophysiology. Am J Physiol: Cell Physiol 2001; 281: C1Y11.
34. Punzi L, Oliviero F, Ramonda R. Transforming growth factor-beta levels in synovial fluid of osteoarthritis with or without calcium pyrophosphate dihydrate crystals. J Rheumatol 2003; 30: 420.
35. Rosenthal AK, Henry LA. Retinoic acid stimulated pyrophosphate elaboration by cartilage and chondrocytes. Calcif Tissue Int 1996; 59: 128-33.
36. Ryan L, Kurup I, Cheung H. Stimulation of inorganic pyrophosphate elaboration by ascorbate. Matrix 1991; 11: 276-81.
37. Lotz M, Rosen F, McCabe G, et al. Interleukin 1 beta suppresses transforming growth factorinduced inorganic pyrophosphate production and expression of the PPi-generating enzyme PC-1 in human chondrocytes Proc Natl Acad USA 1995; 92: 10364-68.
38. Olmez U, Ryan L, Kurup I, Rosenthal A. Insulin-like growth factor-1 suppresses pyrophosphate elaboration by transforming growth factor beta 1 stimulated chondrocytes and cartilage. Osteoarthritis Cart 1994; 2: 149-54.
39. Derfus B, Kranendonk S, Camacho N, et al. Human osteoarthritic cartilage matrix vesicles generate both calcium pyrophosphate dihydrate and apatite in vitro. Calcif Tissue Int 1998; 63: 258-62.
40. Kirsch T, Nah HD, Shapiro IM, Pacifici M. Regulated production of mineralization-competent matrix vesicles in hypertrophic chondrocytes. J Cell Biol 1997; 137: 1149-60.
41. Kirsch T, Harrison G, Golub EE, Nah HD. The roles of annexins and types II and X collagen in matrix vesicle-mediated mineralization of growth plate cartilage. J Biol Chem 2000; 275: 35577-83.
42. Einhorn TA, Gordon SL, Siegel SA, et al. Matrix vesicle enzymes in human osteoarthritis. J Orthop Res 1985; 3: 160-9.
43. Johnson K, Pritzker K, Goding J, Terkeltaub R. The nucleoside triphosphate pyrophosphohydrolase isozyme PC-1 directly promotes cartilage calcification through chondrocyte apoptosis and increased calcium precipitation by mineralizing vesicles. J Rheumatol 2001; 28: 2681-91.
44. Hsu HHT, Camacho NP, Anderson HC. Further characterization of ATP initiated calcification by matrix vesicles isolated from rachitic rat cartilage: membrane perturbation by detergents and deposition of calcium pyrophosphate by rachitic matrix vesicles. Biochimica Biophysica Acta 1999; 1416: 320-32.
45. Defus BA, Kurtin SM, Camacho NP, et al. Comparison of matrix vesicles derived from normal and osteoarthritic human articular cartilage. Connective Tissue Research 1996; 35: 391-6.
46. Chen C-C, Boskey AL, Rosenberg LC. The inhibitory effect of cartilage proteoglycans on hydroxyapatite growth. Calcif Tissue Int 1984; 36: 285-90.
47. Ishikawa K, Masuda I, Ohira T, Yokoyama M. A histological study of calcium pyrophosphate dihydrate crystal-deposition disease. J Bone Joint Surg Am 1989; 71: 875-86.
48. Mandel NS, Mandel GS, Carroll DJ, Halverson PB. Calcium pyrophosphate crystal deposition. An in vitro study using a gelatin matrix model. Arthritis Rheum 1984; 27: 789-96.
49. Thouverey C, Bechkoff G, Pikula S, Buchet R. Inorganic pyrophosphate as a regulator of hydroxyapatite or calcium pyrophosphate dihydrate mineral deposition by matrix vesicles. Osteoarthritis Cartilage 2009; 17: 64-72.
50. Doherty M, Chuck A, Hosking D, Hamilton E. Inorganic pyrophosphate in metabolic diseases predisposing to calcium pyrophosphate dihydrate crystal deposition. Arthritis Rheum 1991; 34: 1297-303.
51. Terkeltaub R, Lotz M, Johnson K, et al. Parathyroid hormone-related proteins is abundant in osteoarthritic cartilage, and the parathyroid hormone-related protein 1-173 isoform is selectively induced by transforming growth factor beta in articular chondrocytes and suppresses generation of extracellular inorganic pyrophosphate. Arthritis Rheum 1998; 41: 2152-64.
52. Calò L, Punzi L, Semplicini A. Hypomagnesemia and chondrocalcinosis in Bartter's and Gitelman's syndrome: review of the pathogenetic mechanisms. Am J Nephrol 2000; 20: 347-50.
53. Bennett RM, Lehr JR, McCarty DJ. Factors affecting the solubility of calcium pyrophosphate dihydrate crystals. J Clin Invest. 1975; 56: 1571-9.